ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma
Cancer Science · 29.10.2026
DOI: 10.1111/cas.70571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 29.10.2026. Verfasst von Minxin He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wu Jieping Medical Foundation Scientific Research Special Project, Key Project of IIT Clinical Research Fund, The Second Affiliated Hospital of Xi‧an Jiaotong University.
Abstract (Originalsprache)
Detection of circulating tumor cells (CTCs), particularly characterization of their epithelial‐mesenchymal transition (EMT) phenotypes, may improve prognostic accuracy for malignancies. Identification of novel biomarkers for CTC classification may improve the characterization of tumor progression and provide potential therapeutic insights for renal cell carcinoma (RCC). Herein, we identified that a disintegrin and metalloproteinase domain‐containing protein 19 (ADAM19) was associated with EMT phenotypes of CTCs. In vitro functional experiments, Western blotting, and RNA sequencing demonstrated that ADAM19 promoted RCC malignant progression and EMT‐related changes and was associated with NOTCH and NF‐κB signaling pathways. Our findings further suggested potential bidirectional association between ADAM19 and these signaling pathways. CTCs isolated from xenograft mouse models exhibited enhanced proliferative, migratory, and invasive abilities, accompanied by increased ADAM19 expression compared with parental tumor cells. Clinical CTC analysis further revealed that ADAM19‐Low‐CTCs were associated with unfavorable clinical outcomes in RCC patients. Notably, higher time‐updated ADAM19‐Low‐CTC counts were identified as an independent risk factor for progression‐free survival (HR = 1.243, 95% CI: 1.006–1.536).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Pathology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
ORCID-Profile: Tie Chong, Zhenlong Wang
Förderung
- Wu Jieping Medical Foundation Scientific Research Special Project
- Key Project of IIT Clinical Research Fund, The Second Affiliated Hospital of Xi‧an Jiaotong University
Zitieren
APA
He, M., Li, M., Ma, Y., Chen, Z., Guo, L., Wang, X., Wang, W., Chong, T., & Wang, Z. (2026). ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma. Cancer Science. https://doi.org/10.1111/cas.70571
Vancouver
He M, Li M, Ma Y, Chen Z, Guo L, Wang X, et al. ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma. Cancer Science. 2026. doi:10.1111/cas.70571
BibTeX
@article{He2026,
author = {He, Minxin and Li, Mingrui and Ma, Yifei and Chen, Zhenzhuo and Guo, Lingyu and Wang, Xiangyu and Wang, Wenjing and Chong, Tie and Wang, Zhenlong},
title = {ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70571}
}
EUVIMED